ID

38316

Descrizione

Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01422408

collegamento

https://clinicaltrials.gov/show/NCT01422408

Keywords

versioni (1)
  1. 09/10/19 09/10/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

9 ottobre 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Carcinoma NCT01422408

Inglese

Eligibility Breast Carcinoma NCT01422408

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult women (both pre-menopausal and post-menopausal women are eligible) and with a history of breast cancer or with an increased risk for breast cancer on current treatment with tamoxifen or an aromatase inhibitor with the presence of vaginal dryness or dyspareunia of sufficient severity to make the subject patient desire therapeutic intervention
Descrizione

Adult | Gender | Premenopausal state | Postmenopausal state | Breast Carcinoma | Risk Increased Breast Carcinoma | Tamoxifen | Aromatase Inhibitors | Vaginal dryness | Treatment required for Dyspareunia Severe

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0079399
UMLS CUI [3]
C0232969
UMLS CUI [4]
C0232970
UMLS CUI [5]
C0678222
UMLS CUI [6,1]
C0035647
UMLS CUI [6,2]
C0205217
UMLS CUI [6,3]
C0678222
UMLS CUI [7]
C0039286
UMLS CUI [8]
C0593802
UMLS CUI [9]
C0241633
UMLS CUI [10,1]
C0332121
UMLS CUI [10,2]
C0013394
UMLS CUI [10,3]
C0205082
vaginal dryness or dyspareunia must be present for at least two months prior to study entry
Descrizione

Vaginal dryness Disease length | Dyspareunia Disease length

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0241633
UMLS CUI [1,2]
C0872146
UMLS CUI [2,1]
C0013394
UMLS CUI [2,2]
C0872146
subjects must be on current treatment with tamoxifen or an aromatase inhibitor for at least two months prior to study enrollment (defined as the date of consent) and should not be planning to discontinue treatment or to change dose or type of endocrine treatment during the duration of the study
Descrizione

Tamoxifen | Aromatase Inhibitors | Treatment Unchanged | Hormone Therapy Dose Unchanged

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0039286
UMLS CUI [2]
C0593802
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0442739
UMLS CUI [4,1]
C0279025
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0442739
subjects must agree to not use any over-the-counter or prescription vaginal preparations (lubricants, creams, gels, ointments, solutions) during the four weeks of treatment with topical fluocinonide cream
Descrizione

Vaginal preparations Absent | Vaginal lubricants Absent | Vaginal Cream Absent | Vaginal Gel Absent | Vaginal Ointment Absent | Vaginal solution Absent | Fluocinonide Topical Cream

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2064912
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0356770
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0042238
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0042257
UMLS CUI [4,2]
C0332197
UMLS CUI [5,1]
C0991586
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C1273007
UMLS CUI [6,2]
C0332197
UMLS CUI [7]
C1252953
subjects must agree to not use any medications, products, or preparations known to contain estrogen during the four weeks of treatment with topical fluocinonide cream
Descrizione

Absence Pharmaceutical Preparations Containing Estrogens | Fluocinonide Topical Cream

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C0332256
UMLS CUI [1,4]
C0014939
UMLS CUI [2]
C1252953
eastern cooperative oncology group (ecog) performance status =< 2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
subjects must have ability to read, comprehend, and complete patient questionnaires independently or with assistance
Descrizione

Able to read Questionnaires | Comprehension Questionnaires | Questionnaires Completion | Able to read Questionnaires Assisted | Comprehension Questionnaires Assisted | Questionnaires Completion Assisted

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0586740
UMLS CUI [1,2]
C0034394
UMLS CUI [2,1]
C0162340
UMLS CUI [2,2]
C0034394
UMLS CUI [3,1]
C0034394
UMLS CUI [3,2]
C0205197
UMLS CUI [4,1]
C0586740
UMLS CUI [4,2]
C0034394
UMLS CUI [4,3]
C1269765
UMLS CUI [5,1]
C0162340
UMLS CUI [5,2]
C0034394
UMLS CUI [5,3]
C1269765
UMLS CUI [6,1]
C0034394
UMLS CUI [6,2]
C0205197
UMLS CUI [6,3]
C1269765
subjects must sign informed consent
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
subjects must agree to read patient instructions regarding use of barrier contraceptive devices while on treatment with fluocinonide cream in the informed consent
Descrizione

Patient instructions Barrier Contraception

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2051542
UMLS CUI [1,2]
C0004764
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of any vaginal preparations within one week prior to study enrollment (exception: subjects currently using a vaginal preparation can enroll after discontinuing treatment for 7 days)
Descrizione

Vaginal preparations | Exception Vaginal preparations Discontinued

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2064912
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C2064912
UMLS CUI [2,3]
C1444662
use of any estrogen containing medications, products, or preparations
Descrizione

Pharmaceutical Preparations Containing Estrogens

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332256
UMLS CUI [1,3]
C0014939
use of any systemic oral or parenteral steroid containing medications is not permitted; use of "high daily dose" inhaled/intranasal corticosteroids is not permitted; use inhaled/intranasal corticosteroid preparations at dosing levels less than "high daily dose" is permitted
Descrizione

Systemic steroids Oral | Systemic steroids Parenteral | inhaled steroids High dose Daily | Corticosteroid use Intranasal High dose Daily

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2825233
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C2825233
UMLS CUI [2,2]
C1518896
UMLS CUI [3,1]
C2065041
UMLS CUI [3,2]
C0444956
UMLS CUI [3,3]
C0332173
UMLS CUI [4,1]
C0239126
UMLS CUI [4,2]
C0001560
UMLS CUI [4,3]
C0444956
UMLS CUI [4,4]
C0332173
current or past treatment with fluocinonide cream for vaginal dryness, itching, or dyspareunia
Descrizione

Fluocinonide Cream Vaginal dryness | Fluocinonide Cream Pruritus of vagina | Fluocinonide Cream Dyspareunia

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1252953
UMLS CUI [1,2]
C0241633
UMLS CUI [2,1]
C1252953
UMLS CUI [2,2]
C0042256
UMLS CUI [3,1]
C1252953
UMLS CUI [3,2]
C0013394
subject reported symptoms of vaginal infection with significant vaginal discharge or odor
Descrizione

Symptoms Vaginal infection | Vaginal Discharge | Vaginal odor

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0404521
UMLS CUI [2]
C0227791
UMLS CUI [3]
C0235678
known current vaginal infection
Descrizione

Vaginal infection

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0404521
known vaginal pathology other than vaginal atrophy that could explain vaginal symptoms
Descrizione

Vaginal Disease | Exception Atrophy of vagina | Explanation Symptoms Vaginal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0042251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0241616
UMLS CUI [3,1]
C0681841
UMLS CUI [3,2]
C1457887
UMLS CUI [3,3]
C4317111
known intolerance of topical steroid preparations
Descrizione

Intolerance to Topical steroids

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C2064827
pregnant or lactating women (to be obtained via subject report only)
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
known diagnoses of diabetes mellitus, adrenal insufficiency (addison's disease), or cushing's syndrome
Descrizione

Diabetes Mellitus | Adrenal gland hypofunction | Addison Disease | Cushing Syndrome

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0001623
UMLS CUI [3]
C0001403
UMLS CUI [4]
C0010481
no prior chemotherapeutic treatment for any malignancy other than breast cancer
Descrizione

Prior Chemotherapy Malignant Neoplasms | Exception Breast Carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0678222
Ritorna all'inizio della pagina

Similar models

Eligibility Breast Carcinoma NCT01422408

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Gender | Premenopausal state | Postmenopausal state | Breast Carcinoma | Risk Increased Breast Carcinoma | Tamoxifen | Aromatase Inhibitors | Vaginal dryness | Treatment required for Dyspareunia Severe
Item
adult women (both pre-menopausal and post-menopausal women are eligible) and with a history of breast cancer or with an increased risk for breast cancer on current treatment with tamoxifen or an aromatase inhibitor with the presence of vaginal dryness or dyspareunia of sufficient severity to make the subject patient desire therapeutic intervention
boolean
C0001675 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0232969 (UMLS CUI [3])
C0232970 (UMLS CUI [4])
C0678222 (UMLS CUI [5])
C0035647 (UMLS CUI [6,1])
C0205217 (UMLS CUI [6,2])
C0678222 (UMLS CUI [6,3])
C0039286 (UMLS CUI [7])
C0593802 (UMLS CUI [8])
C0241633 (UMLS CUI [9])
C0332121 (UMLS CUI [10,1])
C0013394 (UMLS CUI [10,2])
C0205082 (UMLS CUI [10,3])
Vaginal dryness Disease length | Dyspareunia Disease length
Item
vaginal dryness or dyspareunia must be present for at least two months prior to study entry
boolean
C0241633 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0013394 (UMLS CUI [2,1])
C0872146 (UMLS CUI [2,2])
Tamoxifen | Aromatase Inhibitors | Treatment Unchanged | Hormone Therapy Dose Unchanged
Item
subjects must be on current treatment with tamoxifen or an aromatase inhibitor for at least two months prior to study enrollment (defined as the date of consent) and should not be planning to discontinue treatment or to change dose or type of endocrine treatment during the duration of the study
boolean
C0039286 (UMLS CUI [1])
C0593802 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0442739 (UMLS CUI [3,2])
C0279025 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0442739 (UMLS CUI [4,3])
Vaginal preparations Absent | Vaginal lubricants Absent | Vaginal Cream Absent | Vaginal Gel Absent | Vaginal Ointment Absent | Vaginal solution Absent | Fluocinonide Topical Cream
Item
subjects must agree to not use any over-the-counter or prescription vaginal preparations (lubricants, creams, gels, ointments, solutions) during the four weeks of treatment with topical fluocinonide cream
boolean
C2064912 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0356770 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0042238 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0042257 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0991586 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C1273007 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
C1252953 (UMLS CUI [7])
Absence Pharmaceutical Preparations Containing Estrogens | Fluocinonide Topical Cream
Item
subjects must agree to not use any medications, products, or preparations known to contain estrogen during the four weeks of treatment with topical fluocinonide cream
boolean
C0332197 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0332256 (UMLS CUI [1,3])
C0014939 (UMLS CUI [1,4])
C1252953 (UMLS CUI [2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status =< 2
boolean
C1520224 (UMLS CUI [1])
Able to read Questionnaires | Comprehension Questionnaires | Questionnaires Completion | Able to read Questionnaires Assisted | Comprehension Questionnaires Assisted | Questionnaires Completion Assisted
Item
subjects must have ability to read, comprehend, and complete patient questionnaires independently or with assistance
boolean
C0586740 (UMLS CUI [1,1])
C0034394 (UMLS CUI [1,2])
C0162340 (UMLS CUI [2,1])
C0034394 (UMLS CUI [2,2])
C0034394 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0586740 (UMLS CUI [4,1])
C0034394 (UMLS CUI [4,2])
C1269765 (UMLS CUI [4,3])
C0162340 (UMLS CUI [5,1])
C0034394 (UMLS CUI [5,2])
C1269765 (UMLS CUI [5,3])
C0034394 (UMLS CUI [6,1])
C0205197 (UMLS CUI [6,2])
C1269765 (UMLS CUI [6,3])
Informed Consent
Item
subjects must sign informed consent
boolean
C0021430 (UMLS CUI [1])
Patient instructions Barrier Contraception
Item
subjects must agree to read patient instructions regarding use of barrier contraceptive devices while on treatment with fluocinonide cream in the informed consent
boolean
C2051542 (UMLS CUI [1,1])
C0004764 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Vaginal preparations | Exception Vaginal preparations Discontinued
Item
use of any vaginal preparations within one week prior to study enrollment (exception: subjects currently using a vaginal preparation can enroll after discontinuing treatment for 7 days)
boolean
C2064912 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C2064912 (UMLS CUI [2,2])
C1444662 (UMLS CUI [2,3])
Pharmaceutical Preparations Containing Estrogens
Item
use of any estrogen containing medications, products, or preparations
boolean
C0013227 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C0014939 (UMLS CUI [1,3])
Systemic steroids Oral | Systemic steroids Parenteral | inhaled steroids High dose Daily | Corticosteroid use Intranasal High dose Daily
Item
use of any systemic oral or parenteral steroid containing medications is not permitted; use of "high daily dose" inhaled/intranasal corticosteroids is not permitted; use inhaled/intranasal corticosteroid preparations at dosing levels less than "high daily dose" is permitted
boolean
C2825233 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C2825233 (UMLS CUI [2,1])
C1518896 (UMLS CUI [2,2])
C2065041 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C0332173 (UMLS CUI [3,3])
C0239126 (UMLS CUI [4,1])
C0001560 (UMLS CUI [4,2])
C0444956 (UMLS CUI [4,3])
C0332173 (UMLS CUI [4,4])
Fluocinonide Cream Vaginal dryness | Fluocinonide Cream Pruritus of vagina | Fluocinonide Cream Dyspareunia
Item
current or past treatment with fluocinonide cream for vaginal dryness, itching, or dyspareunia
boolean
C1252953 (UMLS CUI [1,1])
C0241633 (UMLS CUI [1,2])
C1252953 (UMLS CUI [2,1])
C0042256 (UMLS CUI [2,2])
C1252953 (UMLS CUI [3,1])
C0013394 (UMLS CUI [3,2])
Symptoms Vaginal infection | Vaginal Discharge | Vaginal odor
Item
subject reported symptoms of vaginal infection with significant vaginal discharge or odor
boolean
C1457887 (UMLS CUI [1,1])
C0404521 (UMLS CUI [1,2])
C0227791 (UMLS CUI [2])
C0235678 (UMLS CUI [3])
Vaginal infection
Item
known current vaginal infection
boolean
C0404521 (UMLS CUI [1])
Vaginal Disease | Exception Atrophy of vagina | Explanation Symptoms Vaginal
Item
known vaginal pathology other than vaginal atrophy that could explain vaginal symptoms
boolean
C0042251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0241616 (UMLS CUI [2,2])
C0681841 (UMLS CUI [3,1])
C1457887 (UMLS CUI [3,2])
C4317111 (UMLS CUI [3,3])
Intolerance to Topical steroids
Item
known intolerance of topical steroid preparations
boolean
C1744706 (UMLS CUI [1,1])
C2064827 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
pregnant or lactating women (to be obtained via subject report only)
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Diabetes Mellitus | Adrenal gland hypofunction | Addison Disease | Cushing Syndrome
Item
known diagnoses of diabetes mellitus, adrenal insufficiency (addison's disease), or cushing's syndrome
boolean
C0011849 (UMLS CUI [1])
C0001623 (UMLS CUI [2])
C0001403 (UMLS CUI [3])
C0010481 (UMLS CUI [4])
Prior Chemotherapy Malignant Neoplasms | Exception Breast Carcinoma
Item
no prior chemotherapeutic treatment for any malignancy other than breast cancer
boolean
C1514457 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial